XM nie świadczy usług obywatelom Stanów Zjednoczonych.
B
B

BayerAG


Wiadomości

Ashmore, Biomerieux, Diasorin

EUROPE RESEARCH ROUNDUP-Ashmore, Biomerieux, Diasorin Oct 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Ashmore, Biomerieux and Diasorin, on Thursday. HIGHLIGHTS * Ashmore ASHM.L : JP Morgan raises target price to 161p from 155p * Biomerieux BIOX.PA : HSBC raises target price to EUR 126 from EUR 120 * Diasorin DIAS.MI : HSBC cuts to hold from buy * Givaudan SA GIVN.S : Citigroup cuts target price to CHF 4650 from CHF 4750 * Oxf
A
A
A
A
B
B
C
D
E
E
G
G
I
L
L
S
T
W
Q
A
A
A
D
U

Australia's Enlitic gains on distribution deal with Bayer Healthcare

BUZZ-Australia's Enlitic gains on distribution deal with Bayer Healthcare ** Shares of Enlitic ENL.AX rise 14.1% to A$0.073, set for best day since Sept. 30, if current gains hold ** Healthcare technology firm says it has signed a three-year distribution contract with multinational biomedical co Bayer Healthcare ** Under the contract, Enlitic says
B

Bayer submits EU marketing application for menopause relief drug

Bayer submits EU marketing application for menopause relief drug Oct 15 (Reuters) - Bayer BAYGn.DE on Tuesday said it had applied for marketing authorization with the European Medicines Agency (EMA) for its menopause relief drug elinzanetant. The daily pill was shown to ease hot flashes in a third late-stage trial that provided supporting data on efficacy and long-term safety.
B

Bayer applies for third indication of Nubeqa in EU

Bayer applies for third indication of Nubeqa in EU BERLIN, Oct 14 (Reuters) - Bayer BAYGn.DE said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as darolutamide, in combination with androgen deprivation therapy. It said the submission to the European Medicines Agency (EMA) was based on positive results from a phase III trial that showed darolutamide plus androgen deprivation therapy (ADT) significantly reduced the risk of radiological progression or d
B

Bayer Submits Application For Third Indication Of Darolutamide In EU

BRIEF-Bayer Submits Application For Third Indication Of Darolutamide In EU Oct 14 (Reuters) - BAYER AG BAYGn.DE : SUBMITS APPLICATION FOR THIRD INDICATION OF DAROLUTAMIDE IN EU IS SEEKING APPROVAL FOR USE OF DAROLUTAMIDE IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) SUBM
B

Bayer slips after verdict to pay $78 mln in Roundup cancer case

BUZZ-Bayer slips after verdict to pay $78 mln in Roundup cancer case ** Shares of Germany's Bayer BAYGn.DE slip 1.7% after a state court jury in Philadelphia found the company must pay $78 million in latest Roundup cancer trial ** The verdict follows previous consecutive victories for Bayer in that court ** New setback after PCB review, a local tra
B

US judicial panel to examine litigation finance disclosure

UPDATE 1-US judicial panel to examine litigation finance disclosure Adds comment from litigation funding group in paragraph 16 By Nate Raymond Oct 10 (Reuters) - A federal judicial rules-making panel on Thursday agreed to study whether a nationwide rule requiring disclosure of third-party litigation funding in lawsuits is necessary at the urging of major companies, business groups and Republican lawmakers .
A
B
C
G
N
P

US judicial panel to examine litigation finance disclosure

US judicial panel to examine litigation finance disclosure By Nate Raymond Oct 10 (Reuters) - A federal judicial rules-making panel on Thursday agreed to study whether a nationwide rule requiring disclosure of third-party litigation funding in lawsuits is necessary at the urging of major companies, business groups and Republican lawmakers . After a decade of weighing whether it should do anything to regulate the emerging field of litigation finance, the U.S.
A
B
C
G
N
P

Bayer must pay $78 million in latest Roundup cancer trial, jury finds

UPDATE 2-Bayer must pay $78 million in latest Roundup cancer trial, jury finds Adds statement from plaintiffs' lawyers in paragraphs 3-4, background in paragraph 10 By Brendan Pierson Oct 10 (Reuters) - Bayer BAYGn.DE must pay $78 million to a Pennsylvania man who said he got cancer from using the company's Roundup weedkiller, a state court jury in Philadelphia found on Thursday.
B

Bayer must pay $78 mln in latest Roundup cancer trial, jury finds

Bayer must pay $78 mln in latest Roundup cancer trial, jury finds By Brendan Pierson Oct 10 (Reuters) - Bayer BAYGn.DE must pay $78 million to a Pennsylvania man who said he got cancer from using the company's Roundup weedkiller, a state court jury in Philadelphia found on Thursday. The verdict in state court in Philadelphia follows previous consecutive victories for Bayer in that court.
B

Bayer falls after US court accepts PCB case for review

BUZZ -Bayer falls after US court accepts PCB case for review ** Shares in Bayer BAYGn.DE fall 7%, with an analyst pointing to new developments in a case over unit Monsanto's toxic chemicals known as PCBs as the potential reason for the move ** Bloomberg on Wednesday reported that Washington state's Supreme Court accepted to review a case against Ba
B

Bayer's Hot Flash Drug Elinzanetant New Drug Application Accepted by US Food And Drug Administration (FDA)

BRIEF-Bayer's Hot Flash Drug Elinzanetant New Drug Application Accepted by US Food And Drug Administration (FDA) Oct 9 (Reuters) - BAYER AG BAYGn.DE : U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS NEW DRUG APPLICATION FOR ELINZANETANT Further company coverage: [BAYGn.DE] (Gdansk Newsroom)
B

Bayer And MOMA Therapeutics Enter Collaboration And License Agreement In Oncology

BRIEF-Bayer And MOMA Therapeutics Enter Collaboration And License Agreement In Oncology Oct 8 (Reuters) - BAYER AG BAYGn.DE : BAYER AND MOMA THERAPEUTICS ENTER COLLABORATION AND LICENSE AGREEMENT IN ONCOLOGY BAYER WILL BE RESPONSIBLE FOR COMPLETING FURTHER PRECLINICAL, DEVELOPMENT AND COMMERCIAL ACTIVITIES FINANCIAL TERMS OF COLLABORATION WERE NOT DISCLOSED.
B

US lawmaker calls for litigation funding disclosures

US lawmaker calls for litigation funding disclosures By Sara Merken Oct 7 (Reuters) - A federal lawmaker has introduced legislation that would require the disclosure of third-party funding in civil lawsuits. U.S. Republican Representative Darrell Issa of California on Friday introduced a bill that calls for parties in civil litigation to tell the court and other named parties the identity of third-party that has the right to receive payment that is contingent on the outcome of a case or group or
A
B
C
G
N
P

Companies ask US judiciary group to force lawsuit funding disclosures

UPDATE 1-Companies ask US judiciary group to force lawsuit funding disclosures Adds comment in paragraphs 11, 12 from funding advocate By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits.
A
B
C
G
N
P

Companies ask US judiciary group to force lawsuit funding disclosures

UPDATE 1-Companies ask US judiciary group to force lawsuit funding disclosures Adds comment in paragraphs 11, 12 from funding advocate By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits.
A
B
C
G
N
P

Companies ask US judiciary group to force lawsuit funding disclosures

Companies ask US judiciary group to force lawsuit funding disclosures By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits. Companies including Amazon.com, Google, Cisco, Meta, Comcast, Exxon, Zurich, Eli Lilly, Bayer, Ford, Pfizer and Novartis submitted the letter on Wednesday to the federal cou
A
B
C
G
N
P

Bayer sees Intacta2 Xtend GMO seed covering 30% of Brazil's soybeans

Bayer sees Intacta2 Xtend GMO seed covering 30% of Brazil's soybeans SAO PAULO, Oct 3 (Reuters) - Germany's Bayer BAYGn.DE forecasts that some 30% of Brazil's soybean area will be sowed with its genetically modified biotech seed Intacta2 Xtend in the 2024/25 season, doubling the share from the previous crop, a top executive said this week. The exact share Intacta2 Xtend will reach should be clear only in some two or three weeks after expected rains allow a broad planting in Brazil's soy fields,
B

India's Shivalik Rasayan climbs on US FDA approval for facility

BUZZ-India's Shivalik Rasayan climbs on US FDA approval for facility ** Shares of Shivalik Rasayan SIVA.NS rise 13.1% to 639.9 rupees ** Agrochemicals and active pharma ingredients (API)-maker received U.S. FDA approval for its API facility in India's Gujarat state ** Stock eyes best day since July 3 ** SIVA down ~14% YTD; agrochemical rivals UPL U
B

ADNOC German deal is blueprint for Gulf takeovers

BREAKINGVIEWS-ADNOC German deal is blueprint for Gulf takeovers The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Karen Kwok LONDON, Oct 1 (Reuters Breakingviews) - Abu Dhabi National Oil Company (ADNOC) has succeeded where other Gulf buyers failed. After more than a year of negotiation, the Emirati oil giant led by Sultan al-Jaber has finally struck a deal to buy German chemical company Covestro 1COV.DE for 14.7 billion euros including debt.
B



Warunki

Popularne aktywa

Wyłączenie odpowiedzialności: Każdy z podmiotów należących do XM Group świadczy usługę polegającą wyłącznie na realizacji zleceń i dostępie do naszej internetowej platformy transakcyjnej, umożliwiając danej osobie przeglądanie i/lub korzystanie z treści dostępnych na stronie lub za jej pośrednictwem, co nie ma na celu zmiany lub rozszerzenia tego zakresu, ani nie zmienia i nie rozszerza go. Taki dostęp i korzystanie z niego podlegają w każdej chwili: (i) Warunkom umowy, (ii) Ostrzeżeniom o ryzyku i (iii) Pełnemu wyłączeniu odpowiedzialności. Treści te są zatem podawane wyłącznie jako informacje ogólne. W szczególności należy pamiętać, że treści zawarte na naszej internetowej platformie transakcyjnej nie stanowią oferty ani zaproszenia do zawarcia jakichkolwiek transakcji na rynkach finansowych. Transakcje na każdym rynku finansowym wiążą się ze znacznym poziomem ryzyka dla twojego kapitału.

Wszystkie materiały publikowane na naszej internetowej platformie transakcyjnej są przeznaczone wyłącznie do celów edukacyjnych/informacyjnych i nie zawierają – i nie powinny być uważane za zawierające – porad ani rekomendacji dotyczących finansów, inwestycji, podatków lub transakcji, zapisu naszych cen transakcyjnych, ani też oferty lub zaproszenia do transakcji na jakichkolwiek instrumentach lub niezamówionych promocji finansowych.

Wszelkie treści pochodzące od podmiotów trzecich, jak i treści przygotowane przez XM, takie jak opinie, wiadomości, badania, analizy, ceny i inne informacje lub linki do stron podmiotów trzecich zawarte na tej stronie internetowej są udostępniane na zasadzie „tak, jak jest” jako ogólny komentarz rynkowy i nie stanowią porady inwestycyjnej. W zakresie, w jakim jakakolwiek treść jest interpretowana jako badania inwestycyjne, należy zauważyć i zaakceptować, że treść ta nie była przeznaczona i nie została przygotowana zgodnie z wymogami prawnymi mającymi na celu promowanie niezależności badań inwestycyjnych i jako taka byłaby uważana za komunikat marketingowy w świetle odpowiednich przepisów prawnych i regulacji. Upewnij się, że przeczytałeś(-aś) i rozumiesz nasze dokumenty Powiadomienie o zależnych badaniach inwestycyjnych oraz Ostrzeżenie o ryzyku, dotyczące powyższych informacji, do których można uzyskać dostęp tutaj.

Ostrzeżenie o ryzyku: Twój kapitał jest zagrożony. Produkty z zastosowaniem dźwigni mogą nie być odpowiednie dla każdego inwestora. Zapoznaj się z Ujawnieniem ryzyka.